<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: significant increases", fill: "#fffafa"},
{source: "3: significant increases", target: "3: increasingly accepted by physicians", fill: "#fffafa"},
{source: "3: increasingly accepted by physicians", target: "3: laboratories", fill: "#fffafa"},
{source: "3: significant increases", target: "4: success depend upon continued increasing acceptance by", fill: "#7df9ff"},
{source: "4: success depend upon continued increasing acceptance by", target: "4: laboratories", fill: "#7df9ff"},
{source: "4: laboratories", target: "4: screening as", fill: "#7df9ff"},
{source: "4: screening as", target: "4: necessary", fill: "#7df9ff"},
{source: "4: necessary", target: "4: cervical cancer screening", fill: "#7df9ff"},
{source: "4: cervical cancer screening", target: "4: specifically", fill: "#7df9ff"},
{source: "4: specifically", target: "4: test products as", fill: "#7df9ff"},
{source: "4: test products as", target: "4: primary cervical cancer screening method", fill: "#7df9ff"},
{source: "4: primary cervical cancer screening method", target: "4: conjunction", fill: "#7df9ff"},
{source: "4: conjunction", target: "4: tests independent", fill: "#7df9ff"},
{source: "4: tests independent", target: "4: implementation", fill: "#7df9ff"},
{source: "4: implementation", target: "4: vaccinations", fill: "#7df9ff"},
{source: "4: success depend upon continued increasing acceptance by", target: "7: Currently ", fill: "#0247fe"},
{source: "7: Currently ", target: "7: approximately", fill: "#0247fe"},
{source: "7: approximately", target: "7: United States ", fill: "#0247fe"},
{source: "7: Currently ", target: "12: significant resources", fill: "#734f96"},
{source: "12: significant resources", target: "12: educate physicians", fill: "#734f96"},
{source: "12: educate physicians", target: "12: laboratories about", fill: "#734f96"},
{source: "12: laboratories about", target: "12: test products", fill: "#734f96"},
{source: "12: test products", target: "12: assist laboratory customers", fill: "#734f96"},
{source: "12: assist laboratory customers", target: "12: learning how", fill: "#734f96"},
{source: "12: significant resources", target: "30: only fully commercialized", fill: "#0f0"},
{source: "30: only fully commercialized", target: "30: detection", fill: "#0f0"},
{source: "30: detection", target: "30: significant", fill: "#0f0"},
{source: "30: significant", target: "30: public domain", fill: "#0f0"},
{source: "30: public domain", target: "30: next few years", fill: "#0f0"},
{source: "30: next few years", target: "30: exclusive basis", fill: "#0f0"},
{source: "30: only fully commercialized", target: "43: tests although", fill: "#483d8b"},
{source: "43: tests although", target: "43: approved by", fill: "#483d8b"},
{source: "43: approved by", target: "43: regulatory", fill: "#483d8b"},
{source: "43: regulatory", target: "43: authorities", fill: "#483d8b"},
{source: "43: authorities", target: "43: alternative", fill: "#483d8b"},
{source: "43: alternative", target: "43: test products", fill: "#483d8b"},
{source: "43: test products", target: "43: could limit", fill: "#483d8b"},
{source: "43: could limit", target: "43: laboratory customer base", fill: "#483d8b"},
{source: "43: tests although", target: "44: activities", fill: "#6d9bc3"},
{source: "44: activities", target: "50: Chief Executive Officer ", fill: "#8db600"},
{source: "50: Chief Executive Officer ", target: "211: directors", fill: "#fff5ee"},
{source: "211: directors", target: "211: authority without further action by", fill: "#fff5ee"},
{source: "211: authority without further action by", target: "211: stockholders", fill: "#fff5ee"},
{source: "211: stockholders", target: "211: preferred stock", fill: "#fff5ee"},
{source: "211: preferred stock", target: "211: preferences", fill: "#fff5ee"},
{source: "211: preferences", target: "211: such preferred stock", fill: "#fff5ee"},
{source: "211: directors", target: "START_HERE", fill: "#fff5ee"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_testing">Product testing</a></td>
      <td>Product testing, also called consumer testing or comparative testing, is a process of measuring the properties or performance of products.\nThe theory is that since the advent of mass production, manufacturers produce branded products which they assert and advertise to be identical within some technical standard.Product testing seeks to ensure that consumers can understand what products will do for them and which products are the best value.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cross_product">Cross product</a></td>
      <td>In mathematics, the cross product or vector product (occasionally directed area product, to emphasize its geometric significance) is a binary operation on two vectors in a three-dimensional oriented  Euclidean vector space (named here \n  \n    \n      \n        E\n      \n    \n    {\displaystyle E}\n  ), and is denoted by the symbol \n  \n    \n      \n        ×\n      \n    \n    {\displaystyle \times }\n  . Given two linearly independent vectors a and b, the cross product, a × b (read "a cross b"), is a vector that is perpendicular to both a and b, and thus normal to the plane containing them.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cannabis_product_testing">Cannabis product testing</a></td>
      <td>Cannabis product testing is product testing of the properties of cannabis destined for consumer use. Analytical chemistry and microbiology laboratories determine cannabinoids, water content, heavy metals, pesticides, terpenes, yeast, mold and mycotoxins, and solvents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_testing">Software testing</a></td>
      <td>Software testing is the act of examining the artifacts and the behavior of the software under test by validation and verification. Software testing can also provide an objective, independent view of the software to allow the business to appreciate and understand the risks of software implementation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fire_test">Fire test</a></td>
      <td>A fire test is a means of determining whether fire protection products meet minimum performance criteria as set out in a building code or other applicable legislation. Successful tests in laboratories holding national accreditation for testing and certification result in the issuance of a certification listing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Device_under_test">Device under test</a></td>
      <td>A device under test (DUT), also known as equipment under test (EUT) and unit under test (UUT), is a manufactured product undergoing testing, either at first manufacture or later during its life cycle as part of ongoing functional testing and calibration checks. This can include a test after repair to establish that the product is performing in accordance with the original product specification.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Portable_appliance_testing">Portable appliance testing</a></td>
      <td>In electrical safety testing, portable appliance testing (PAT, PAT inspection or redundantly as PAT testing) is a process in the United Kingdom, the Republic of Ireland, New Zealand and Australia by which electrical appliances are routinely checked for safety. The formal term for the process is "in-service inspection &amp; testing of electrical equipment".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Conformance_testing">Conformance testing</a></td>
      <td>Conformance testing — an element of conformity assessment, and also known as compliance testing, or type testing — is testing or other activities that determine whether a process, product, or service complies with the requirements of a specification, technical standard, contract, or regulation. Testing is often either logical testing or physical testing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Democratic_Party_(United_States)">Democratic Party (United States)</a></td>
      <td>The Democratic Party is one of the two major contemporary political parties in the United States. It was founded in 1828 by supporters of Andrew Jackson, making it the world's oldest active political party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Marine_Corps">United States Marine Corps</a></td>
      <td>The United States Marine Corps (USMC), also referred to as the United States Marines, is the maritime land force service branch of the United States Armed Forces responsible for conducting expeditionary and amphibious operations through combined arms, implementing its own infantry, artillery, aerial, and special operations forces. The U.S. Marine Corps is one of the eight uniformed services of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_dollar">United States dollar</a></td>
      <td>The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official currency of the United States and several other countries. The Coinage Act of 1792 introduced the U.S. dollar at par with the Spanish silver dollar, divided it into 100 cents, and authorized the minting of coins denominated in dollars and cents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Limulus_amebocyte_lysate">Limulus amebocyte lysate</a></td>
      <td>Limulus amebocyte lysate (LAL) is an aqueous extract of blood cells (amoebocytes) from the Atlantic horseshoe crab Limulus polyphemus. LAL reacts with bacterial endotoxin lipopolysaccharide (LPS), which is a membrane component of gram-negative bacteria.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chief_executive_officer">Chief executive officer</a></td>
      <td>A chief executive officer (CEO), also known as a central executive officer (CEO), chief administrator officer (CAO), or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization –  especially an independent legal entity such as a company or nonprofit institution. CEOs find roles in a range of organizations, including public and private corporations, non-profit organizations and even some government organizations (notably state-owned enterprises).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Board_of_directors">Board of directors</a></td>
      <td>A board of directors (commonly referred simply as the board) is an executive committee that jointly supervises the activities of an organization, which can be either a for-profit or a nonprofit organization such as a business, nonprofit organization, or a government agency. \nThe powers, duties, and responsibilities of a board of directors are determined by government regulations (including the jurisdiction's corporate law) and the organization's own constitution and by-laws.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Directors'_Fortnight">Directors' Fortnight</a></td>
      <td>The Directors' Fortnight (French: Quinzaine des Réalisateurs) is an independent selection of the Cannes Film Festival. It was started in 1969 by the French Directors Guild after the events of May 1968 resulted in cancellation of the Cannes festival as an act of solidarity with striking workers.The Directors' Fortnight showcases a programme of shorts and feature films and documentaries worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Creative_director">Creative director</a></td>
      <td>A creative director (or creative supervisor) is a person that makes high-level creative decisions, and with those decisions oversees the creation of creative assets such as advertisements, products, events, or logos. Creative director positions are often found within the television production, graphic design, film, music, video game, fashion, advertising, media, or entertainment industries, but may be useful in other creative organizations such as web development and software development firms as well.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Film_director">Film director</a></td>
      <td>A film director controls a film's artistic and dramatic aspects and visualizes the screenplay (or script) while guiding the film crew and actors in the fulfilment of that vision. The director has a key role in choosing the cast members, production design and all the creative aspects of filmmaking.The film director gives direction to the cast and crew and creates an overall vision through which a film eventually becomes realized or noticed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Executive_director">Executive director</a></td>
      <td>An executive director is a member of a board of directors for an organisation, but the meaning of the term varies between countries.\n\n\n== United States ==\nIn the US, an executive director is a chief executive officer (CEO) or managing director of an organization, company, or corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nelson_(director)">Nelson (director)</a></td>
      <td>Nelson Dilipkumar, credited in films as Nelson, is an Indian director and screenwriter who predominantly works in Tamil cinema. His films are known for featuring elements of Dark Humour.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bala_(director)">Bala (director)</a></td>
      <td>Balasubramanian known as Bala is an Indian film director, screenwriter, and producer, working in Tamil cinema. Often considered to be one of the finest directors in Tamil, Bala is widely acclaimed for "revolutionizing Tamil cinema" through his realistic, dark and disturbing depiction of the working class on celluloid screen.Just within directing a handful of films, his movies went on to win 6 National Awards, 13 State awards, 15 Filmfare Awards, 14 International Festival Awards and numerous coveted state awards which created a storm within the Indian movie scene.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><font color="blue">Before     </font>making  an <font color="blue">investment decision</font>, you <font color="blue">should carefully</font> consider the risk     <font color="blue">factors set forth</font> below</td>
    </tr>
    <tr>
      <td>We will not be able to achieve <font color="blue"><font color="blue">significant</font> increases</font> in our revenues if HPV     screening is not <font color="blue">increasingly accepted by physicians</font> and <font color="blue">laboratories</font></td>
    </tr>
    <tr>
      <td>Our growth and <font color="blue">success <font color="blue">depend upon</font> continued increasing acceptance by</font>     physicians and <font color="blue">laboratories</font> of HPV <font color="blue">screening as</font> a <font color="blue">necessary</font> part of the     standard of care for <font color="blue"><font color="blue">cervical cancer</font> screening</font> and, more <font color="blue">specifically</font>, of     our HPV <font color="blue"><font color="blue">test products</font> as</font> a primary <font color="blue"><font color="blue">cervical cancer</font> screening</font> method, in     <font color="blue">conjunction</font> with Pap tests, independent of Pap tests, and in <font color="blue">conjunction</font>     with  the  <font color="blue">implementation</font> of HPV <font color="blue"><font color="blue">vaccination</font>s</font></td>
    </tr>
    <tr>
      <td>Pap tests have been the     principal means of <font color="blue"><font color="blue">cervical cancer</font> screening</font> since the 1940s</td>
    </tr>
    <tr>
      <td><font color="blue">Technological     </font><font color="blue">advances designed</font> to <font color="blue">improve quality control over</font> sample <font color="blue">collection</font> and     <font color="blue">preservation</font> and to reduce the Pap test’s susceptibility to <font color="blue">human error may</font>     <font color="blue">increase physician reliance on</font> the Pap test and solidify its <font color="blue">market position</font>     as the <font color="blue">most widely used screen</font> for <font color="blue">cervical cancer</font></td>
    </tr>
    <tr>
      <td>Currently, <font color="blue">approximately</font>     60 million Pap tests are performed annually in the <font color="blue"><font color="blue">United States</font> </font>and we     believe that 60 to 100 million are performed annually in the rest of the     world</td>
    </tr>
    <tr>
      <td>Women with normal Pap tests do not undergo follow-up treatment beyond     routine  Pap  testing</td>
    </tr>
    <tr>
      <td>Follow-up testing and treatment is <font color="blue">based on</font> the     classification of the Pap test result</td>
    </tr>
    <tr>
      <td>An equivocal, or ASC-US (Atypical     Squamous Cells of Undetermined Significance), classification is given to Pap     test results that cannot be <font color="blue">definitively classified as either normal</font> or     abnormal; this classification occurs in <font color="blue">approximately</font> 5prca to 7prca of all cases</td>
    </tr>
    <tr>
      <td>HPV testing applies a new gene-based <font color="blue">technology</font> and <font color="blue">testing approach</font>     that is <font color="blue">different from</font> the cytology (reviewing cells under a microscope)     approach of the Pap test</td>
    </tr>
    <tr>
      <td>We have expended, and need to continue to spend,     <font color="blue"><font color="blue">significant</font> resources</font> to <font color="blue">educate physicians</font> and <font color="blue">laboratories</font> about the     patient  benefits  that can result from using our HPV <font color="blue">test products</font> in     addition to the Pap test, and to <font color="blue">assist <font color="blue">laboratory customers</font></font> in <font color="blue">learning how</font>     to perform our HPV <font color="blue">test products</font></td>
    </tr>
    <tr>
      <td>Using our HPV <font color="blue">test products</font> along with the     Pap test for <font color="blue">primary screening</font> in the <font color="blue"><font color="blue">United States</font> </font>may be seen by some of     these customers as adding un<font color="blue">necessary</font> expense to the <font color="blue"><font color="blue">generally</font> accepted</font>     <font color="blue"><font color="blue">cervical cancer</font> screening</font> methodology and we <font color="blue">frequently</font> need to provide     information to counteract this <font color="blue">impression on</font> a case-by-case basis</td>
    </tr>
    <tr>
      <td>To date,     we have been able to grow our US <font color="blue"><font color="blue">revenues from</font> sales</font> of our HPV test     products from <font color="blue">approximately</font> dlra24cmam354cmam000 in fiscal 2002 to <font color="blue">approximately</font>     dlra111cmam746cmam000 in fiscal 2006</td>
    </tr>
    <tr>
      <td>We believe that with these efforts we have     captured  <font color="blue">approximately</font>  18prca  of the HPV <font color="blue">testing market</font></td>
    </tr>
    <tr>
      <td>If we are not     successful in executing our marketing strategies, we may not be able to     <font color="blue"><font color="blue">significant</font>ly grow</font> our market share for HPV testing, and we will not be able     to continue to grow our revenues</td>
    </tr>
    <tr>
      <td>During  fiscal  2006 we expanded our direct-to-consumer awareness     <font color="blue"><font color="blue">marketing program</font>s</font> because we believe a <font color="blue">well educated female population will</font>     work with their <font color="blue">health care providers</font> to increase the use of The Digene HPV     Test</td>
    </tr>
    <tr>
      <td>The campaign to <font color="blue">date involved national print advertisement</font> and focused     <font color="blue">television advertising</font> in <font color="blue">ten locations</font>, Atlanta, Baltimore, Philadelphia,     Boston,  Chicago,  Houston,  Dallas,  New York City, San Francisco and     Washington,  DC We plan to continue our direct-to-consumer awareness     campaign in fiscal 2007, and to move into other markets in fiscal 2007</td>
    </tr>
    <tr>
      <td>If     we are not successful in executing this <font color="blue">marketing program</font>, we may not be     able to <font color="blue"><font color="blue">significant</font>ly increase</font> the sales of our HPV tests to the extent we     desire</td>
    </tr>
    <tr>
      <td>received FDA approval for a vaccine     against  HPV  types 16 and 18, the high-risk HPV <font color="blue">types <font color="blue">associated with</font></font>     <font color="blue">approximately</font>  70prca  of  cervical  cancer  cases</td>
    </tr>
    <tr>
      <td>We  anticipate  that     <font color="blue">GlaxoSmithKline </font>will receive FDA approval for an HPV <font color="blue">vaccine product during</font>     our fiscal 2007</td>
    </tr>
    <tr>
      <td>We are working with our physician and <font color="blue">laboratory customers</font>     and <font color="blue">with others</font> to develop and establish the role HPV <font color="blue">screening will play</font> in     the standard of care for HPV <font color="blue">vaccination</font></td>
    </tr>
    <tr>
      <td>If we are not successful in this     endeavor,  we may not be able to <font color="blue"><font color="blue">significant</font>ly grow</font> the market for HPV     screening or increase our HPV <font color="blue">test revenues</font></td>
    </tr>
    <tr>
      <td>27       _________________________________________________________________                Our  products  for the <font color="blue">diagnosis</font> of the presence of chlamydia and     <font color="blue">gonorrhea compete with</font> other FDA-cleared products that detect the presence     of <font color="blue">such infectious diseases</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">marketing <font color="blue">activities</font> focus on providing</font>     information regarding the accuracy and objective nature of these <font color="blue">diagnostic</font>     tests, but such <font color="blue">activities</font> are time-consuming and expensive</td>
    </tr>
    <tr>
      <td>We believe the     best  way  to  increase our <font color="blue">revenues from</font> these products is to educate     <font color="blue">laboratories</font> and <font color="blue">physicians about</font> the ability to <font color="blue">run such tests from</font> the     <font color="blue">same patient</font> sample collected for HPV testing</td>
    </tr>
    <tr>
      <td>If we are not successful in     executing our <font color="blue">marketing strategy</font> we do not expect to <font color="blue"><font color="blue">significant</font>ly grow</font> our     <font color="blue">revenues from</font> these products</td>
    </tr>
    <tr>
      <td>We  have  the  <font color="blue">only fully <font color="blue">commercialize</font>d</font> and FDA-approved test for the     <font color="blue">detection</font> of HPV, <font color="blue">which provides us with</font> a <font color="blue"><font color="blue">competitive</font> advantage</font> that may be     <font color="blue"><font color="blue">adversely</font> impacted</font> if other companies develop and <font color="blue"><font color="blue">commercialize</font> <font color="blue">alternative</font></font>     HPV tests</td>
    </tr>
    <tr>
      <td>Although we have the <font color="blue">only fully <font color="blue">commercialize</font>d</font> and FDA-approved test     for  the  <font color="blue">detection</font>  of  HPV, a <font color="blue">significant</font> portion of our HPV-related     <font color="blue"><font color="blue">intellectual</font> property</font> is in the <font color="blue">public domain</font>, subject to patents that will     begin to expire in the <font color="blue">next few years</font> or not licensed to us on a sole and     <font color="blue">exclusive basis</font></td>
    </tr>
    <tr>
      <td>As a result, we believe other companies are developing or     will develop HPV <font color="blue">detection</font> tests in the <font color="blue">next few years</font></td>
    </tr>
    <tr>
      <td>For example, F Hoffman-La Roche Ltd</td>
    </tr>
    <tr>
      <td>(Roche) has publicly announced     its <font color="blue">ongoing <font color="blue">development</font></font> of a test for the <font color="blue">detection</font> of <font color="blue">HPV and in April </font>2004     announced that it <font color="blue">launched such test</font> in Europe</td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>2005, <font color="blue">Roche     </font>announced an <font color="blue">agreement with</font> Gen-Probe Incorporated to supply HPV DNA probes     to Gen-Probe for its HPV test kits</td>
    </tr>
    <tr>
      <td>In June 2002, <font color="blue">Institut Pasteur </font>announced     that it had transferred its HPV <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> estate</font> to Roche, which     included an <font color="blue">assignment</font> of the <font color="blue">cross license between</font> Digene and Institut     Pasteur</td>
    </tr>
    <tr>
      <td>Based upon the HPV types to which Roche has announced that it     acquired <font color="blue">access as</font> a result of the <font color="blue">transfer by</font> Institut Pasteur, the HPV     <font color="blue">types covered by</font> Roche’s own patents and the HPV types that are publicly     available, and despite our <font color="blue">continuing exclusive</font> right to <font color="blue">certain high risk</font>     HPV types, we believe Roche may have the ability to develop a HPV test that     would be <font color="blue"><font color="blue">competitive</font> with</font> our HPV <font color="blue">test products</font> in our <font color="blue">principal markets</font></td>
    </tr>
    <tr>
      <td>Roche has <font color="blue">substantially greater resources than</font> we do</td>
    </tr>
    <tr>
      <td>We may not be able to     <font color="blue">compete <font color="blue">successfully</font> against</font> Roche if it markets a HPV test <font color="blue"><font color="blue">competitive</font> with</font>     our HPV test</td>
    </tr>
    <tr>
      <td>Ventana Medical Systems, Inc</td>
    </tr>
    <tr>
      <td>is selling an in situ <font color="blue">diagnostic</font> test for     the  <font color="blue">detection</font>  of  HPV  We believe Ventana’s <font color="blue"><font color="blue">activities</font> infringe</font> our     <font color="blue"><font color="blue">intellectual</font> property</font> and we have <font color="blue">initiated patent infringement <font color="blue">litigation</font></font>     against Ventana</td>
    </tr>
    <tr>
      <td>If we are not successful in <font color="blue">such <font color="blue">litigation</font></font>, and if Ventana     obtains FDA approval for a test <font color="blue"><font color="blue">competitive</font> with</font> our HPV <font color="blue">test products</font>, we     may lose <font color="blue">significant</font> HPV <font color="blue">testing revenue</font> to Ventana</td>
    </tr>
    <tr>
      <td>We are also aware that a <font color="blue">significant</font> number of <font color="blue">laboratory <font color="blue">organizations</font></font>     and  other companies are developing and <font color="blue">using internally</font> developed, or     “home-brew,” HPV tests</td>
    </tr>
    <tr>
      <td>These tests, although not <font color="blue">approved by</font> the FDA or     similar non-US <font color="blue">regulatory</font> <font color="blue">authorities</font>, do offer an <font color="blue">alternative</font> to our HPV     <font color="blue">test products</font> that <font color="blue">could limit</font> the <font color="blue">laboratory customer base</font> for our product</td>
    </tr>
    <tr>
      <td>We are monitoring these <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent on</font> a <font color="blue">relatively</font> small number of national <font color="blue">laboratories</font> for a     <font color="blue">significant</font> portion of our sales to <font color="blue">laboratory customers</font></td>
    </tr>
    <tr>
      <td>We supply our HPV <font color="blue">test products</font> to national <font color="blue">laboratories</font>, such as Quest     Diagnostics and LabCorp pursuant to standard, non-exclusive fixed term     contracts</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> customer could decide to                                         28       _________________________________________________________________           terminate or not renew its <font color="blue">existing contract with us</font></td>
    </tr>
    <tr>
      <td>The loss of one or     more <font color="blue">significant</font> customers could have a material adverse effect on our     business</td>
    </tr>
    <tr>
      <td><font color="blue">Changes  </font>in  our  senior  <font color="blue">management</font>  team could impact our ability to     <font color="blue">successfully</font> operate and grow our business</td>
    </tr>
    <tr>
      <td>During fiscal 2007 both our current Chief Executive Officer, and our     current President, Chief Operating Officer and Chief Financial Officer will     leave Digene</td>
    </tr>
    <tr>
      <td>The Nominating and Corporate Governance Committee of our Board     of Directors is <font color="blue">currently conducting</font> a search for a new Chief Executive     Officer</td>
    </tr>
    <tr>
      <td>Such changes in our senior <font color="blue">management</font> team, and the <font color="blue">activities</font>     <font color="blue">associated with</font> identifying and selecting a new <font color="blue">Chief Executive Officer </font>    could divert <font color="blue">management</font> attention from our core business, and could have a     <font color="blue">negative impact on</font> our ability to implement our <font color="blue">strategic <font color="blue">objectives</font></font> and     grow  our business</td>
    </tr>
    <tr>
      <td>We are highly <font color="blue">dependent on</font> the <font color="blue">remaining principal</font>     members of our <font color="blue">management</font> staff</td>
    </tr>
    <tr>
      <td>Loss of <font color="blue">additional</font> <font color="blue">key personnel</font> would     likely impede <font color="blue">achievement</font> of our research and <font color="blue">development</font>, operational, or     strategic  <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>To  be  successful,  we <font color="blue">must attract qualified</font>     <font color="blue">replacements</font> for our <font color="blue">departing executives</font>, retain <font color="blue">key employees</font> and attract     <font color="blue">additional</font> qualified employees</td>
    </tr>
    <tr>
      <td>We <font color="blue">may encounter <font color="blue"><font color="blue">difficult</font>ies</font> expanding</font> our <font color="blue"><font color="blue">manufacturing</font> <font color="blue">operations</font> as</font>     demand  for  our products increases, which would <font color="blue">negatively impact</font> our     revenues</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> a <font color="blue">single <font color="blue">facility</font></font> for the <font color="blue">manufacture</font> of all of our     <font color="blue">diagnostic</font> test kits and any <font color="blue">temporary stoppage at</font> that site would have a     material adverse effect on our business</td>
    </tr>
    <tr>
      <td>If <font color="blue">product sales increase</font>, we will have to scale-up our <font color="blue">manufacturing</font>     processes  and <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>We may encounter <font color="blue"><font color="blue">difficult</font>ies</font> in scaling-up     <font color="blue">manufacturing</font>  processes  and  may  be <font color="blue">unsuccessful</font> in <font color="blue">overcoming such</font>     <font color="blue"><font color="blue">difficult</font>ies</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">such circumstances</font>, our ability to <font color="blue"><font color="blue">meet product demand</font> may</font>     be impaired or delayed</td>
    </tr>
    <tr>
      <td>We  have a single <font color="blue">manufacturing</font> <font color="blue">facility</font> located in Gaithersburg,     Maryland</td>
    </tr>
    <tr>
      <td>This <font color="blue">facility</font> is subject, on an <font color="blue">ongoing basis</font>, to a variety of     quality systems <font color="blue">regulations</font>, international quality standards and other     <font color="blue">regulatory</font> <font color="blue">requirements</font>, including current good <font color="blue">manufacturing</font> practices     <font color="blue">requirements</font>  of the FDA We may encounter <font color="blue"><font color="blue">difficult</font>ies</font> maintaining or     expanding our <font color="blue">manufacturing</font> <font color="blue">operations</font> in <font color="blue">accordance with</font> these <font color="blue">regulations</font>     and standards, <font color="blue">which could</font> result in a delay or <font color="blue">termination</font> of <font color="blue">manufacturing</font>     or an <font color="blue">inability</font> to <font color="blue">meet product demand</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">face risks inherent</font> in operating as a <font color="blue">single <font color="blue">facility</font></font> for the     <font color="blue">manufacture</font> of our products</td>
    </tr>
    <tr>
      <td>We do not have <font color="blue">alternative</font> production plans in     place  or  <font color="blue">alternative</font> <font color="blue">facilities</font> available if we experience prolonged     <font color="blue">facility</font> failure at our Gaithersburg, Maryland <font color="blue">manufacturing</font> <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>risks include unforeseen <font color="blue">manufacturing</font> delays or <font color="blue">stoppage due</font> to equipment,     raw material supply disruption, <font color="blue">regulatory</font>, environmental or other factors,     and the resulting <font color="blue">inability</font> to <font color="blue">meet customer orders on</font> a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">successfully</font> integrate future <font color="blue">acquisitions</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">continually explore opportunities</font> to acquire related <font color="blue">businesses</font>,     some of <font color="blue">which could</font> be material to us</td>
    </tr>
    <tr>
      <td>Our ability to continue to grow may     <font color="blue">depend upon</font> identifying and <font color="blue">successfully</font> acquiring <font color="blue">attractive companies</font>,     <font color="blue"><font color="blue">effectively</font> integrating such companies</font>, achieving <font color="blue">cost efficiencies</font> and     managing these <font color="blue">businesses</font> as part of our company</td>
    </tr>
    <tr>
      <td>We may not be able to     <font color="blue">effectively</font>  integrate  acquired  companies and <font color="blue">successfully</font> implement     appropriate operational, financial and <font color="blue">management</font> systems and controls to     achieve the benefits expected to result from these <font color="blue">acquisitions</font></td>
    </tr>
    <tr>
      <td>Our effort     to integrate these <font color="blue">businesses</font> could be <font color="blue">affected by</font> a number of factors     beyond  our control, such as <font color="blue">regulatory</font> <font color="blue">development</font>s, general economic     conditions, increased competition, the loss of customers resulting from the     <font color="blue">acquisitions</font> and the <font color="blue">assumption</font> of <font color="blue">unknown <font color="blue">liabilities</font></font></td>
    </tr>
    <tr>
      <td>In addition, the     process of integrating these <font color="blue">businesses</font> could cause an                                         29       _________________________________________________________________           <font color="blue">interruption</font> of, or loss of momentum in, the <font color="blue">activities</font> of our existing     business and the loss of <font color="blue">key personnel</font> and customers</td>
    </tr>
    <tr>
      <td>The diversion of     <font color="blue">management</font>’s  attention  and any delays or <font color="blue"><font color="blue">difficult</font>ies</font> encountered in     <font color="blue">connection with</font> the <font color="blue">integration</font> of these <font color="blue">businesses</font> could <font color="blue">negatively impact</font>     our business if any of the above <font color="blue">adverse effects</font> were to occur</td>
    </tr>
    <tr>
      <td>Further, the     benefits that we anticipate from any future <font color="blue">acquisitions</font> may not develop</td>
    </tr>
    <tr>
      <td>Future  <font color="blue">acquisitions</font>  may  harm  our  operating  results,  dilute  our     <font color="blue">stockholders</font>’ equity and create other financial <font color="blue"><font color="blue">difficult</font>ies</font> for us</td>
    </tr>
    <tr>
      <td>We may in the future pursue <font color="blue">acquisitions</font> that we believe <font color="blue">could provide</font>     us with new technologies, products or <font color="blue">service offerings</font>, or <font color="blue">enable us</font> to     obtain other <font color="blue"><font color="blue">competitive</font> advantage</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font><font color="blue">by us may involve</font> some or all of the <font color="blue">following financial</font>     risks:       •   use of <font color="blue">significant</font> amounts of cash;         •   <font color="blue">potential dilutive issuances</font> of <font color="blue">equity securities</font>;         •   incurrence of debt or <font color="blue">amortization expenses</font> related to certain     <font color="blue">intangible assets</font>; and          •     <font color="blue">future impairment charges</font> related to <font color="blue">diminished fair value</font> of     <font color="blue">businesses</font> acquired as compared to the price we pay for them</td>
    </tr>
    <tr>
      <td>We may not be successful in overcoming the <font color="blue">risks described</font> above or any     other problems <font color="blue">associated with</font> future <font color="blue">acquisitions</font></td>
    </tr>
    <tr>
      <td>Any of these risks and     problems  could  <font color="blue">materially</font> harm our business, prospects and financial     condition</td>
    </tr>
    <tr>
      <td>Additionally, we <font color="blue">cannot guarantee</font> that any companies we may     acquire will achieve anticipated revenues or operating results</td>
    </tr>
    <tr>
      <td>If more third-party health insurance payors do not <font color="blue">adequately reimburse</font> for     our HPV <font color="blue">test products</font>, the use of our HPV <font color="blue">test products</font> may not increase,     <font color="blue"><font color="blue">thus negatively affect</font>ing</font> our ability to grow our revenues</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of the sales of our products in the <font color="blue"><font color="blue">United States</font> </font>    and other <font color="blue">markets depend</font>, in large part, on the <font color="blue">availability</font> of adequate     <font color="blue">reimbursement</font>  to  users of our <font color="blue">tests from government insurance</font> plans,     including  <font color="blue">Medicare  </font>and  Medicaid  in the <font color="blue">United States</font>, <font color="blue">managed care</font>     <font color="blue">organizations</font>  and  <font color="blue">private insurance</font> plans</td>
    </tr>
    <tr>
      <td>We believe we have nearly     <font color="blue">universal coverage from</font> US government payors, third-party payors and     managed  care  entities  for our hc[2] HPV Test as a follow-up test to     <font color="blue">categorize equivocal</font> Pap test results</td>
    </tr>
    <tr>
      <td>In addition, government payors,     third—party payors and <font color="blue">managed care</font> entities that <font color="blue">provide health insurance</font>     coverage to over 225 million people in the <font color="blue"><font color="blue">United States</font> </font><font color="blue">currently authorize</font>     <font color="blue">reimbursement</font> for the use of our <font color="blue">Digene HPV Test </font>to <font color="blue">adjunctively</font> screen     women age 30 and older to assess the presence or absence of <font color="blue">significant</font>,     cancer-causing HPV types</td>
    </tr>
    <tr>
      <td>We also seek <font color="blue">reimbursement</font> coverage in other     countries where we market our products, particularly in Europe, and receipt     of the <font color="blue">necessary</font> approvals is time-consuming and expensive</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement     </font>coverage for the Pap test is universal in the <font color="blue"><font color="blue">United States</font> </font>and in other     markets where we sell our HPV <font color="blue">test products</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">encountered delays</font> in receipt of some European <font color="blue">reimbursement</font>     approvals and public health funding, which has impacted our ability to grow     revenues in these markets</td>
    </tr>
    <tr>
      <td>Despite our success to date, third-party payors are often reluctant to     <font color="blue">reimburse healthcare providers</font> for the use of <font color="blue">medical tests such as</font> our HPV     <font color="blue">test products</font> that <font color="blue">involve new <font color="blue">technology</font></font></td>
    </tr>
    <tr>
      <td>In addition, third-party payors     are increasingly limiting <font color="blue">reimbursement</font> coverage for medical <font color="blue">diagnostic</font>                                         30       _________________________________________________________________           products and, in many instances, are exerting pressure on <font color="blue">diagnostic</font> product     suppliers to reduce their prices</td>
    </tr>
    <tr>
      <td>Thus, third-party <font color="blue">reimbursement</font> may not be     <font color="blue">consistently available</font> or <font color="blue">financially adequate</font> to cover the cost of our     products</td>
    </tr>
    <tr>
      <td>This <font color="blue">could limit</font> our ability to sell our products, cause us to     reduce  the  prices  of our products or <font color="blue">otherwise <font color="blue">adversely</font> affect</font> our     operating results</td>
    </tr>
    <tr>
      <td>Because each third-party payor individually approves <font color="blue">reimbursement</font>,     obtaining  such  approvals is a time-consuming and <font color="blue">costly process</font> that     requires us to <font color="blue">provide scientific</font> and <font color="blue">clinical support</font> for the use of each     of  our  products to <font color="blue">each payor separately with no assurance</font> that such     approval  will  be  obtained</td>
    </tr>
    <tr>
      <td>This process can delay the <font color="blue">broad market</font>     <font color="blue">introduction</font>  of  <font color="blue">new products</font> and could have a negative effect on our     revenues and operating results</td>
    </tr>
    <tr>
      <td>We may need to <font color="blue">initiate lawsuits</font> to protect or enforce our patents, which     would be expensive and, if we lose, may cause us to lose some, if not all,     of our <font color="blue"><font color="blue">intellectual</font> property</font> rights, and <font color="blue">thereby impair</font> our ability to     compete</td>
    </tr>
    <tr>
      <td>We  rely  on  patents to protect a large part of our <font color="blue">intellectual</font>     property</td>
    </tr>
    <tr>
      <td>To protect or enforce our <font color="blue">patent rights</font>, we <font color="blue">may initiate patent</font>     <font color="blue">litigation</font> against <font color="blue">third parties</font>, such as infringement suits or <font color="blue">interference</font>     <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">lawsuits could</font> be expensive, take <font color="blue">significant</font> time and     divert <font color="blue">management</font>’s attention from other business concerns</td>
    </tr>
    <tr>
      <td>They would also     put our <font color="blue">patents at risk</font> of being invalidated or <font color="blue">interpreted narrowly</font>, and     our <font color="blue"><font color="blue">patent <font color="blue">applications</font></font> at risk</font> of not issuing</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also provoke</font> these     <font color="blue">third parties</font> to assert claims <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Patent law relating to the scope     of claims in the <font color="blue"><font color="blue">technology</font> fields</font> in which we operate is <font color="blue">still evolving</font>     and, consequently, <font color="blue">patent position</font>s in our industry are <font color="blue"><font color="blue">generally</font> uncertain</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot <font color="blue">provide as</font>surance</font> that we would prevail in any of these suits or     that the damages or other <font color="blue">remedies awarded</font>, if any, would be <font color="blue">commercially</font>     valuable</td>
    </tr>
    <tr>
      <td>During the course of these potential suits, there may be public     <font color="blue">announcements</font>  of  the  results of hearings, motions and other interim     <font color="blue">proceedings</font> or <font color="blue">development</font>s in the <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Any public <font color="blue">announcements</font>     related to these suits could cause our stock price to decline</td>
    </tr>
    <tr>
      <td>We <font color="blue">may inadvertently infringe upon</font> the <font color="blue"><font color="blue">intellectual</font> property</font> rights of third     parties,  which  could  expose  us  to expensive <font color="blue"><font color="blue">intellectual</font> property</font>     <font color="blue">litigation</font>, impose a <font color="blue">significant</font> strain on our resources and <font color="blue">prevent us from</font>     developing or marketing our products</td>
    </tr>
    <tr>
      <td>There have been substantial <font color="blue">litigation</font> and other <font color="blue">proceedings</font> regarding     patent and other <font color="blue"><font color="blue">intellectual</font> property</font> rights in the <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font> industries</font> because of the <font color="blue">uncertainties</font> and <font color="blue">complex legal</font>,     scientific and factual questions related to the ownership and protection of     <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>We have received inquiries regarding <font color="blue">possible patent</font>     <font color="blue">infringements</font> relating to, among other things, aspects of our <font color="blue"><font color="blue">Hybrid Capture </font>    </font><font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We believe that the patents of others to which these inquiries     relate are either not <font color="blue">infringed by</font> our <font color="blue">Hybrid Capture </font><font color="blue">technology</font> or are     invalid</td>
    </tr>
    <tr>
      <td>However, we may be subject to further claims that our <font color="blue">technology</font>,     including  our <font color="blue">Hybrid Capture </font><font color="blue">technology</font>, or our <font color="blue">products infringe</font> the     patents or <font color="blue"><font color="blue">proprietary</font> rights</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>We may also be forced to     initiate  legal  <font color="blue">proceedings</font>  to  protect our <font color="blue">patent position</font> or other     <font color="blue">proprietary</font>   rights</td>
    </tr>
    <tr>
      <td>These  <font color="blue">proceedings</font>  are  often  expensive  and     time-consuming, even if we were to prevail</td>
    </tr>
    <tr>
      <td>Single suppliers or a limited number of <font color="blue">suppliers provide key <font color="blue">components</font></font> of     our products</td>
    </tr>
    <tr>
      <td>If these <font color="blue">suppliers fail</font> to supply these <font color="blue">components</font>, we may be     unable to <font color="blue">manufacture</font> sufficient product to <font color="blue">satisfy demand which would</font>     <font color="blue">negatively impact</font> our revenues</td>
    </tr>
    <tr>
      <td>Several key <font color="blue">components</font> of our <font color="blue">products come from</font>, or are <font color="blue">manufacture</font>d     for us by, a <font color="blue">single supplier</font> or limited number of suppliers</td>
    </tr>
    <tr>
      <td>This applies in     particular to the following <font color="blue">components</font>, chemiluminescent substrates (used to     create a <font color="blue">chemical reaction</font> that causes light in <font color="blue">connection with</font> our Hybrid     Capture signal amplified molecular <font color="blue">technology</font>), our <font color="blue">Rapid Capture System     </font>that serves as the                                         31       _________________________________________________________________           <font color="blue">automation platform</font> developed for large-scale <font color="blue">diagnostic</font> testing using the     <font color="blue">Hybrid Capture </font><font color="blue">technology</font>, the 96-well microplate used by <font color="blue">laboratories</font> to     run our <font color="blue">diagnostic</font> <font color="blue">test products</font>, the Digene Microplate Luminometer that     provides the results of all of our microplate-based <font color="blue">diagnostic</font> tests, and     the <font color="blue">collection</font> tubes, plus the <font color="blue">cervical sampler brushes</font> we <font color="blue">provide as</font> part     of cervical sampler kits that we sell with our HPV <font color="blue">testing products</font></td>
    </tr>
    <tr>
      <td>We have     been able, to date, to enter into long-term contracts with these single     <font color="blue">source suppliers</font></td>
    </tr>
    <tr>
      <td>In some cases, however, the supplier of a key component is     not required to supply us with specified quantities over longer periods of     time or set-aside part of its inventory for our forecasted <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We     have not arranged for <font color="blue">alternative</font> supply sources for these <font color="blue">components</font> and it     may be <font color="blue">difficult</font> to find <font color="blue">alternative</font> suppliers, if at all</td>
    </tr>
    <tr>
      <td>If our products     <font color="blue">sales increase beyond</font> the <font color="blue">forecast levels</font>, or if our suppliers are unable or     unwilling to supply us <font color="blue">components</font> on a <font color="blue">timely basis</font>, we may be unable to     <font color="blue">satisfy product demand</font></td>
    </tr>
    <tr>
      <td>In addition, if any of the <font color="blue">components</font> of our products are no longer     available  in the marketplace, we may be forced to further develop our     products  or  <font color="blue">technology</font>  to  <font color="blue">incorporate</font>  alternate  <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">incorporation</font> of new <font color="blue">components</font> into our <font color="blue">products may</font> require us to seek     approvals  from  the  FDA  or  foreign  <font color="blue">regulatory</font>  agencies  prior to     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>We are required to obtain and maintain royalty-bearing licenses to third     <font color="blue">party patents</font> or <font color="blue">patent <font color="blue">applications</font></font>, and loss of <font color="blue">such licenses</font>, or the need     to obtain <font color="blue">additional</font> licenses, could <font color="blue">materially</font> <font color="blue">adversely</font> affect our ability     to <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We have in-licensed patents to a number of cancer-causing HPV types,     which, together with the patents to cancer-causing HPV types that we own,     provide  us with a <font color="blue"><font color="blue">competitive</font> advantage</font></td>
    </tr>
    <tr>
      <td>We may lose this <font color="blue">competitive</font>     advantage if these <font color="blue">licenses terminate</font> or if the <font color="blue">patents licensed thereunder</font>     expire or are declared invalid</td>
    </tr>
    <tr>
      <td>Our products and <font color="blue">manufacturing</font> processes require access to biological     materials and other <font color="blue"><font color="blue">intellectual</font> property</font> that may be subject to patents and     <font color="blue">patent <font color="blue">applications</font></font> held by <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In addition, we have licenses to     various patents covering <font color="blue"><font color="blue">intellectual</font> property</font> that we use in <font color="blue">conjunction</font>     <font color="blue">with <font color="blue">applications</font></font> of our <font color="blue">Hybrid Capture </font><font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> have     claims to these patents</td>
    </tr>
    <tr>
      <td>An <font color="blue">adverse outcome</font> to such claims could subject us     to  <font color="blue">significant</font>  <font color="blue">liabilities</font>  to <font color="blue">third parties</font> or require us to obtain     royalty-bearing licenses from <font color="blue">third parties</font>, cease sales of related products     or revise the <font color="blue">applications</font> or <font color="blue">products which employ</font> the patented <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Any licenses required for any such third <font color="blue">party patents</font> or <font color="blue"><font color="blue">proprietary</font> rights</font>     may not be made available to us on <font color="blue">commercially</font> <font color="blue">reasonable terms</font>, if at all</td>
    </tr>
    <tr>
      <td>Furthermore,  we  may be unable to make the <font color="blue">necessary</font> revisions to our     <font color="blue">applications</font> or products</td>
    </tr>
    <tr>
      <td>We <font color="blue">may discover</font> that we need to obtain rights to an <font color="blue">additional</font> patent     in order to <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We may be unable to obtain such     rights on <font color="blue">commercially</font> <font color="blue">reasonable terms</font> or at all, <font color="blue">which could</font> <font color="blue">adversely</font>     affect our ability to grow our business</td>
    </tr>
    <tr>
      <td>We have <font color="blue">incurred cumulative net losses</font> to date and need to continue to spend     substantial  funds</td>
    </tr>
    <tr>
      <td>We may not <font color="blue">remain profitable</font> and may need to seek     <font color="blue">additional</font> financing</td>
    </tr>
    <tr>
      <td>We have had substantial operating losses since <font color="blue">incorporation</font> in 1987</td>
    </tr>
    <tr>
      <td>We turned profitable during the <font color="blue">fourth quarter</font> of fiscal 2003, but prior to     that we <font color="blue">never earned</font> a profit</td>
    </tr>
    <tr>
      <td>At June 30, 2006, our <font color="blue">accumulated deficit</font> was     <font color="blue">approximately</font> dlra53cmam874cmam000</td>
    </tr>
    <tr>
      <td>Previous losses have resulted <font color="blue">principally from</font>:       •   expenses <font color="blue">associated with</font> our research and <font color="blue">development</font> programs;         •   our sales and marketing <font color="blue">activities</font> in the <font color="blue"><font color="blue">United States</font> </font>and     <font color="blue">internationally</font>;                                         32       _________________________________________________________________             •   patent <font color="blue">litigation</font> costs and settlement and licensing expenses; and         •   other expenses, including <font color="blue">administrative</font> and <font color="blue">facilities</font> costs</td>
    </tr>
    <tr>
      <td>We had net     income of <font color="blue">approximately</font> dlra21cmam542cmam000, which included a <font color="blue">deferred tax benefit</font>     of <font color="blue">approximately</font> dlra14cmam900cmam000, in fiscal 2004</td>
    </tr>
    <tr>
      <td>In fiscal 2005, we had a net     loss of <font color="blue">approximately</font> dlra8cmam167cmam000, primarily due to payments made to settle     ongoing  <font color="blue">litigation</font>  matters</td>
    </tr>
    <tr>
      <td>We believe that our <font color="blue">existing capital resources</font>,     together with the proceeds of our 2005 financing, will be sufficient to meet     the anticipated cash needs of our current business for the foreseeable     future</td>
    </tr>
    <tr>
      <td>However, if we incur <font color="blue">significant</font> operating losses or if one or more     of the <font color="blue">events described</font> in these <font color="blue">Risk Factors </font>actually occurs, we may have     to obtain <font color="blue">additional</font> <font color="blue">funds through</font> equity or debt financing, strategic     alliances  with  <font color="blue">corporate partners</font> and others, or through <font color="blue">alternative</font>     sources</td>
    </tr>
    <tr>
      <td>Any <font color="blue">equity financing would dilute</font> our then-current <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>We     do  not have any <font color="blue">committed sources</font> of <font color="blue">additional</font> financing</td>
    </tr>
    <tr>
      <td><font color="blue">Additional     </font>funding, if <font color="blue">necessary</font>, may not be <font color="blue">available on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available, we may have to delay, scale-back or     <font color="blue">eliminate aspects</font> of our <font color="blue">operations</font> or attempt to obtain <font color="blue">funds through</font>     <font color="blue">arrangements with collaborative partners</font> or others</td>
    </tr>
    <tr>
      <td>This may result in the     <font color="blue">relinquishment</font>  of  our  rights  to  some of our technologies, product     <font color="blue">candidates</font>, products or <font color="blue">potential markets</font></td>
    </tr>
    <tr>
      <td>The growth of our European <font color="blue">operations</font> has <font color="blue">been slower than</font> expected, and we     may not achieve the desired increase in our <font color="blue">profitability from such market</font></td>
    </tr>
    <tr>
      <td>In 2002 we made the decision to establish our own sales, marketing,     <font color="blue">distribution</font>, warehousing and <font color="blue">customer support infrastructure</font> in Europe for     the  sale of our HPV <font color="blue">test products</font> and other products</td>
    </tr>
    <tr>
      <td>Other companies     selling medical <font color="blue">diagnostic</font> products in Europe are larger and <font color="blue">significant</font>ly     <font color="blue">better capitalized than</font> we are, and have had established European <font color="blue">operations</font>     for a <font color="blue">significant</font>ly longer period than we have</td>
    </tr>
    <tr>
      <td>We had <font color="blue">previously used</font>     third-party distributors to distribute and market our products in Europe,     and our product inventory, <font color="blue">distribution</font> and customer support services are     still in the <font color="blue">development</font> process</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>dlra11cmam992cmam000, or 19prca, of our     sales and <font color="blue">marketing <font color="blue">expenditure</font>s</font> and <font color="blue">approximately</font> dlra5cmam779cmam000, or 22prca, of     our general and <font color="blue">administrative</font> <font color="blue">expenditure</font>s for fiscal 2006 related to our     <font color="blue">activities</font> in Europe</td>
    </tr>
    <tr>
      <td>During the same period, <font color="blue">approximately</font> dlra16cmam394cmam000, or     12prca, of our HPV <font color="blue">testing revenue</font>s were from sales in Europe</td>
    </tr>
    <tr>
      <td>We expect to     continue  to  expend  <font color="blue">significant</font>  resources  to grow and maintain our     <font color="blue">infrastructure as</font> much <font color="blue">as possible given</font> the <font color="blue">resources at</font> our disposal, but     <font color="blue">such resources may</font> not be sufficient to <font color="blue">meaningfully increase</font> our revenues     in Europe</td>
    </tr>
    <tr>
      <td>Our revenues and operating results could be hurt by our <font color="blue">inability</font>     to <font color="blue">successfully</font> grow and maintain our <font color="blue">distribution</font> infrastructure or our     <font color="blue">inability</font> to <font color="blue">effectively</font> market our products in Europe</td>
    </tr>
    <tr>
      <td>The decision to establish our own infrastructure in Europe has required     us to <font color="blue">establish multiple subsidiary corporations</font> in Europe</td>
    </tr>
    <tr>
      <td>This <font color="blue">subjects us</font>     to the laws of <font color="blue">multiple jurisdictions</font>, including tax and <font color="blue">employment laws</font>,     and the <font color="blue">laws governing</font> the import, storage and <font color="blue">distribution</font> of our products</td>
    </tr>
    <tr>
      <td>Any failure to <font color="blue">comply with</font> these laws could have a material <font color="blue">adverse impact</font>     on our business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The time and expense needed to obtain <font color="blue">regulatory</font> approval and respond to     changes in <font color="blue">regulatory</font> <font color="blue">requirements</font> could <font color="blue">adversely</font> affect our ability to     <font color="blue">commercially</font> distribute our products and <font color="blue">generate revenue therefrom</font></td>
    </tr>
    <tr>
      <td>Each of our products and product <font color="blue">candidates</font> are medical devices subject     to extensive regulation by the FDA under the Federal Food, Drug and Cosmetic     Act</td>
    </tr>
    <tr>
      <td><font color="blue">Governmental  </font>bodies in other <font color="blue">countries also</font> have medical device     approval <font color="blue">regulations</font> which are becoming more extensive</td>
    </tr>
    <tr>
      <td>Such <font color="blue">regulations</font>     govern the majority of the commercial <font color="blue">activities</font> we perform, including the     <font color="blue">indications</font> for which our products can be used, product <font color="blue">development</font>, product     testing, product labeling, product storage, use of our                                         33       _________________________________________________________________           products  with  other  products and the <font color="blue">manufacturing</font>, advertising and     promotion of our products for the approved <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with     these <font color="blue">regulations</font> is expensive and time-consuming</td>
    </tr>
    <tr>
      <td>With respect to our HPV     <font color="blue">test products</font>, we were the <font color="blue">first company</font> to obtain approval of <font color="blue">regulatory</font>     <font color="blue">applications</font> for HPV testing in the <font color="blue"><font color="blue">United States</font> </font>and in many countries in     Europe (our <font color="blue">principal markets</font>), which adds to our expense and increases the     degree  of  <font color="blue">regulatory</font> review and oversight</td>
    </tr>
    <tr>
      <td>The expense of submitting     <font color="blue">regulatory</font> approval <font color="blue">applications</font> in <font color="blue">multiple countries as compared</font> to our     available  resources  impacts the <font color="blue">decisions</font> we make <font color="blue">about entering new</font>     markets</td>
    </tr>
    <tr>
      <td>Each medical device that we wish to distribute <font color="blue">commercially</font> in the     <font color="blue"><font color="blue">United States</font> </font><font color="blue">will likely</font> require either 510(k) clearance or pre-market     <font color="blue">approval from</font> the FDA prior to marketing the device for in vitro-<font color="blue">diagnostic</font>     use</td>
    </tr>
    <tr>
      <td>Clinical trials related to our <font color="blue">regulatory</font> submissions take years to     execute and are a <font color="blue">significant</font> expense for us</td>
    </tr>
    <tr>
      <td>The 510(k) clearance pathway     usually  takes  from  three to twelve months, but can take longer</td>
    </tr>
    <tr>
      <td>The     pre-market approval pathway is much more costly, lengthy and uncertain</td>
    </tr>
    <tr>
      <td>It     <font color="blue">generally</font> takes from one to <font color="blue">three years</font>, but can also take longer</td>
    </tr>
    <tr>
      <td>It took     us more <font color="blue">than four years</font> to receive pre-market approval to offer our current     <font color="blue">generation</font> HPV test product to test for the presence of the HPV in women     with equivocal Pap test results and pre-market approval to use our Digene     HPV  Test as a primary adjunctive <font color="blue"><font color="blue">cervical cancer</font> screening</font> test to be     performed in <font color="blue">conjunction</font> with the Pap test for women age 30 and older</td>
    </tr>
    <tr>
      <td><font color="blue">With     </font>respect to our <font color="blue">ongoing efforts</font>, in April 2002, we submitted a PMA supplement     with the FDA <font color="blue">seeking approval</font> of the use of our hc[2] HPV Test with TriPath     Imaging, Inc</td>
    </tr>
    <tr>
      <td>’s <font color="blue">SurePath Test Pack </font>sample <font color="blue">collection</font> system</td>
    </tr>
    <tr>
      <td>We worked with <font color="blue">TriPath Imaging </font>during fiscal 2004 to complete     <font color="blue">additional</font> clinical studies and submitted the results of these studies to     the <font color="blue">FDA in August </font>2004 for pre-market approval</td>
    </tr>
    <tr>
      <td><font color="blue">In February </font>2005, TriPath     Imaging withdrew the PMA supplement after <font color="blue">TriPath Imaging </font>and the FDA agreed     that <font color="blue">additional</font> clinical information and <font color="blue">analysis would</font> be required</td>
    </tr>
    <tr>
      <td>In     December 2005, <font color="blue">TriPath Imaging </font>resubmitted its PMAS supporting the use of     SurePath <font color="blue">specimens with</font> the hc2 HR HPV Test</td>
    </tr>
    <tr>
      <td>The FDA is <font color="blue">currently reviewing</font>     such  PMAS, and <font color="blue">TriPath Imaging </font>is responding to the FDA’s request for     information</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> time <font color="blue">span increases</font> our costs to develop new     products and increases the risk that we will not succeed in introducing or     selling <font color="blue">new products</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Our cleared or <font color="blue">approved devices</font>, including our <font color="blue">diagnostic</font> tests and     related equipment, are subject to numerous post-market <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We are     subject to inspection and <font color="blue">marketing surveillance by</font> the FDA to determine our     compliance with <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>finds that we have     failed to comply, it can institute a wide variety of <font color="blue">enforcement actions</font>,     <font color="blue">ranging from</font> a <font color="blue">public warning letter</font> to more <font color="blue">severe sanctions such as fines</font>,     <font color="blue">injunctions</font>  and  civil  penalties, recall or seizure of our products,     operating restrictions, partial suspension or <font color="blue">total shutdown</font> of production,     denial  of our requests for 510(k) clearance or pre-market approval of     product <font color="blue">candidates</font>, withdrawal of 510(k) clearance or pre-market approval     <font color="blue">already granted</font>; and <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">enforcement action by</font> the FDA     <font color="blue">may also affect</font> our ability to <font color="blue">commercially</font> distribute our products in the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We may be sued for <font color="blue">product liability</font> claims or <font color="blue">face <font color="blue">product recalls</font></font> for     which our <font color="blue">insurance may</font> be inadequate</td>
    </tr>
    <tr>
      <td>We may be <font color="blue">found liable</font> if any of our products causes injury or fails to     accurately diagnose disease, ie, provides a “false negative” or “false     positive”  test result</td>
    </tr>
    <tr>
      <td>We currently carry <font color="blue">product liability</font> insurance     <font color="blue">coverage with</font> a <font color="blue">combined single limit</font> of dlra10cmam000cmam000</td>
    </tr>
    <tr>
      <td>This <font color="blue">coverage may</font> not     be adequate to protect us against future <font color="blue">product liability</font> claims</td>
    </tr>
    <tr>
      <td><font color="blue">Product     </font>liability <font color="blue">insurance may</font> not be available to us in the future on <font color="blue">commercially</font>     <font color="blue">reasonable terms</font>, if at all</td>
    </tr>
    <tr>
      <td>Our products are a <font color="blue">complex interaction</font> of <font color="blue">biochemical reagents</font>, and it     is not uncommon for us to face <font color="blue">manufacturing</font>, raw material or supply chain     problems</td>
    </tr>
    <tr>
      <td>We have initiated <font color="blue">product recalls</font> from time                                         34       _________________________________________________________________           to time in the past and <font color="blue">additional</font> <font color="blue">product recalls</font> may be <font color="blue">necessary</font> from     time  to  time in the future, either voluntarily on our part or at the     direction of the FDA or other <font color="blue">government agencies</font></td>
    </tr>
    <tr>
      <td>Although none of our past     <font color="blue">product recalls</font> have had a material <font color="blue">adverse impact</font> on our business, we     believe future <font color="blue">product recalls</font> could have a material <font color="blue">adverse affect on</font> our     business, <font color="blue">financial condition</font> or reputation</td>
    </tr>
    <tr>
      <td>Our <font color="blue">international sales</font> are subject to currency, market and <font color="blue">regulatory</font> risks     that are beyond our control</td>
    </tr>
    <tr>
      <td>For fiscal 2006, we derived <font color="blue">approximately</font> 19prca of our <font color="blue">consolidated</font>     revenues  from the <font color="blue">international sales</font> of our products and services in     foreign currencies and we expect that <font color="blue">international sales</font> will continue to     account for a large portion of our sales</td>
    </tr>
    <tr>
      <td>Changes in the rate of exchange of     <font color="blue">foreign currencies into</font> <font color="blue"><font color="blue">United States</font> </font>dollars have and may hurt our revenues     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In particular, we <font color="blue">sell products</font> in, and derive <font color="blue">revenues from</font>, less     <font color="blue">economically</font> developed countries</td>
    </tr>
    <tr>
      <td>During such times, the value of local     currency in <font color="blue">such countries</font> has decreased, sometimes dramatically, negatively     impacting our average unit prices</td>
    </tr>
    <tr>
      <td>In the past, this has     <font color="blue">adversely</font> affected our revenues and operating results</td>
    </tr>
    <tr>
      <td>Future economic and     political  instability  in <font color="blue">foreign countries may affect demand</font> for our     products and the value of the <font color="blue">local currency</font>, and thus, negatively affect     our revenues and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The extent and <font color="blue">complexity</font> of <font color="blue">medical products regulation</font> are increasing     worldwide, particularly in Europe, <font color="blue">with regulation</font> in some <font color="blue">countries nearly</font>     as extensive as in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Further, we must <font color="blue">comply with</font> import     and export <font color="blue">regulations</font> when <font color="blue">distributing</font> our products to <font color="blue">foreign nations</font></td>
    </tr>
    <tr>
      <td>Each foreign country’s <font color="blue">regulatory</font> <font color="blue">requirements</font> for <font color="blue">product approval</font> and     <font color="blue">distribution</font> are unique and may require the <font color="blue">expenditure</font> of substantial time,     money  and  effort</td>
    </tr>
    <tr>
      <td>As  a  result, we may not be able to <font color="blue">successfully</font>     <font color="blue">commercialize</font> our products in foreign markets at or beyond the level of     <font color="blue">commercialization</font> we have already achieved</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font> with  changing  <font color="blue">corporate governance</font> and <font color="blue">public disclosure</font>     <font color="blue">regulations</font> result in <font color="blue">additional</font> expenses</td>
    </tr>
    <tr>
      <td><font color="blue">Changing  </font>laws,  <font color="blue">regulations</font>  and standards relating to corporate     governance and <font color="blue">public disclosure</font>, including the Sarbanes-Oxley Act of 2002,     new <font color="blue">US Securities and Exchange Commission </font><font color="blue">regulations</font> and NASDAQ Stock     Market  rules, are creating <font color="blue">uncertainty</font> for <font color="blue">companies such as ours</font></td>
    </tr>
    <tr>
      <td>To     maintain <font color="blue">high standards</font> of <font color="blue">corporate governance</font> and <font color="blue">public disclosure</font>, we     intend to invest all reasonably <font color="blue">necessary</font> resources to <font color="blue">comply with</font> evolving     standards</td>
    </tr>
    <tr>
      <td>These  investments  have resulted in <font color="blue">increased general</font> and     <font color="blue">administrative</font> expenses and a diversion of <font color="blue">management</font> time and attention     from revenue-generating <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We have adopted anti-takeover provisions that <font color="blue">may prevent</font> or frustrate any     attempt to replace or remove our current <font color="blue">management</font> by the <font color="blue">stockholders</font> or     <font color="blue">discourage bids</font> for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>These provisions <font color="blue">may also affect</font> the     <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font> has the authority, without further action by the     <font color="blue">stockholders</font>,  to  issue, from time to time, up to 1cmam000cmam000 shares of     <font color="blue">preferred stock</font> in one or more classes or series and to fix the rights and     <font color="blue">preferences</font> of such <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>The board of <font color="blue">directors</font> could use this     authority to issue <font color="blue">preferred stock</font> to discourage an <font color="blue">unwanted bidder from</font>     making a proposal to acquire the company</td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of <font color="blue">incorporation</font>     <font color="blue">also provides</font> for <font color="blue">staggered terms</font> for members of the board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>This provision means it could take up to <font color="blue">three years</font> to replace our existing     <font color="blue">directors</font> without the support of the board of                                         35       _________________________________________________________________           <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Additionally, our <font color="blue">bylaws establish</font> an advance notice procedure     for <font color="blue">stockholder proposals</font> and for nominating <font color="blue">candidates</font> for <font color="blue">election as</font>     <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>These provisions of our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws     may  prevent or frustrate any attempt to replace or remove our current     <font color="blue">directors</font>  or <font color="blue">management</font> by <font color="blue">stockholders</font>, which may have the effect of     delaying, deterring or preventing a change in <font color="blue">control transaction</font></td>
    </tr>
    <tr>
      <td>Further, we are subject to provisions of <font color="blue">Delaware </font>corporate law, which,     subject  to  limited exceptions, will prohibit us from engaging in any     “business <font color="blue">combination</font>” with a person who, <font color="blue">together with affiliates</font> and     associates,  owns  15prca  or more of our <font color="blue">common stock</font>, referred to as an     <font color="blue">interested stockholder</font>, for a period of <font color="blue">three years</font> following the date that     such  person  becomes  an  <font color="blue">interested stockholder</font>, unless the business     <font color="blue">combination</font> is <font color="blue">approved by</font> our board of <font color="blue">directors</font> in a <font color="blue">prescribed manner</font></td>
    </tr>
    <tr>
      <td>Although we do not currently have a stockholder that meets the “interested     stockholder” definition, these provisions of <font color="blue">Delaware </font>law may make business     <font color="blue">combination</font>s  more  time consuming or expensive and have the impact of     requiring our board of <font color="blue">directors</font> to <font color="blue">agree with</font> a proposal before it is     accepted  and  presented  to  <font color="blue">stockholders</font>  for  <font color="blue">consideration</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>anti-takeover provisions might <font color="blue">discourage bids</font> for our <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>